Abiopharma

Protalix BioTherapeutics Letter to Stockholders

Merck to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones

Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer’s Disease Agitation

LYB to discuss fourth-quarter results Friday, Jan. 30, 2026

Rockwell Medical Extends Product Purchase Agreement Through 2026 With One of the Largest Dialysis Providers in the United States

IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference

NUTEX HEALTH TO ATTEND AND PRESENT AT THE 2026 J.P. MORGAN HEALTHCARE CONFERENCE IN JANUARY IN SAN FRANCISCO

ProPhase Labs Provides Update on Convertible Debt Conversions, Capital Structure, and Underlying Asset Value

Media Release: Hyphens Pharma out-licences Cerapro® MED Skin Barrier Cream for six European countries